Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Inks Israeli Distribution Deal for Cancer MDx

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has signed an agreement making clinical services provider Best Med Opinion the exclusive distributor of Interpace’s cancer molecular diagnostics in Israel.

Under the terms of the deal, Tel Aviv-based Best Med will provide Israeli physicians and patients with information regarding Interpace's ThyGenX and ThyraMir tests for thyroid cancer, as well as its PancraGen pancreatic cancer test. It will also oversee the collection and shipment of test samples to Interpace's CLIA labs and report the results back to ordering physicians.

Additional terms were not disclosed.

"We are excited about our relationship with Best Med," Interpace President and CEO Jack Stover said in a statement. "Their selection of our products and services is an important validation of our potential to expand internationally."

During early morning trading on Nasdaq, shares of Interpace were up 45 percent at $6.70. Earlier this week, the company announced that it had regained compliance with Nasdaq's minimum bid requirement and that it has submitted a plan to the exchange to regain compliance with its minimum stockholder's equity requirement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.